155 related articles for article (PubMed ID: 16320269)
1. Modelling intervention effects after cancer relapses.
González JR; Peña EA; Slate EH
Stat Med; 2005 Dec; 24(24):3959-75. PubMed ID: 16320269
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of prognostic factors in children with B-cell non-Hodgkin lymphoma (B-NHL)].
Zajac-Spychała O; Derwich K; Mańkowska M; Konatkowska B; Mańkowski P; Wachowiak J
Med Wieku Rozwoj; 2008; 12(4 Pt 2):1087-91. PubMed ID: 19531831
[TBL] [Abstract][Full Text] [Related]
4. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
[TBL] [Abstract][Full Text] [Related]
5. Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission.
Truong Q; Shah N; Knestrick M; Curley B; Hu Y; Craig M; Hamadani M
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):50-5. PubMed ID: 24119465
[TBL] [Abstract][Full Text] [Related]
6. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA; Chavez JC; Sehgal AR; William BM; Munoz J; Salles G; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Yakoub-Agha I; Oluwole OO; Fung HCH; Rosenblatt J; Rossi JM; Goyal L; Plaks V; Yang Y; Vezan R; Avanzi MP; Neelapu SS
Lancet Oncol; 2022 Jan; 23(1):91-103. PubMed ID: 34895487
[TBL] [Abstract][Full Text] [Related]
7. Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma.
El-Galaly TC; Mylam KJ; Bøgsted M; Brown P; Rossing M; Gang AO; Haglund A; Arboe B; Clausen MR; Jensen P; Pedersen M; Bukh A; Jensen BA; Poulsen CB; d'Amore F; Hutchings M
Am J Hematol; 2014 Jun; 89(6):575-80. PubMed ID: 24493389
[TBL] [Abstract][Full Text] [Related]
8. Relapsed non-Hodgkin's lymphoma: detection and treatment.
Shioyama Y; Nakamura K; Kunitake N; Kimura M; Terashima H; Masuda K
Radiat Med; 2000; 18(6):369-75. PubMed ID: 11153690
[TBL] [Abstract][Full Text] [Related]
9. Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
Wang Y; Farooq U; Link BK; Larson MC; King RL; Maurer MJ; Allmer C; Hefazi M; Thompson CA; Micallef IN; Johnston PB; Habermann TM; Witzig TE; Ansell SM; Cerhan JR; Nowakowski GS
J Clin Oncol; 2019 Jul; 37(21):1819-1827. PubMed ID: 31170029
[TBL] [Abstract][Full Text] [Related]
10. Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.
Wudhikarn K; Brunstein CG; Bachanova V; Burns LJ; Cao Q; Weisdorf DJ
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1497-504. PubMed ID: 21338707
[TBL] [Abstract][Full Text] [Related]
11. Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.
Ram R; Gooley TA; Maloney DG; Press OW; Pagel JM; Petersdorf SH; Shustov AR; Flowers ME; O'Donnell P; Sandmaier BM; Storb RF; Gopal AK
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1537-45. PubMed ID: 21536145
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study.
Schommers P; Gillor D; Hentrich M; Wyen C; Wolf T; Oette M; Zoufaly A; Wasmuth JC; Bogner JR; Müller M; Esser S; Schleicher A; Jensen B; Stoehr A; Behrens G; Schultze A; Siehl J; Thoden J; Taylor N; Hoffmann C
Haematologica; 2018 May; 103(5):857-864. PubMed ID: 29439188
[TBL] [Abstract][Full Text] [Related]
13. Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell support.
Johnsen HE; Björkstrand B; Carlson K; Gruber A; Blystad A; Fast A; Boesen AM; Björkholm M; Sallerfors B; Ruutu T; Carneskog J; Malm A; Geisler C; Lehtinen M; Schrøder H; Brinch L; Remes K; Tidefelt U; Heilmann C; Hörnsten P; Thorling K; Daugaard G
Leuk Lymphoma; 1996 Dec; 24(1-2):81-91. PubMed ID: 9049964
[TBL] [Abstract][Full Text] [Related]
14. Semiparametric Inference for a General Class of Models for Recurrent Events.
Peña EA; Slate EH; González JR
J Stat Plan Inference; 2007 Jun; 137(6):1727-1747. PubMed ID: 19823592
[TBL] [Abstract][Full Text] [Related]
15. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.
Mikhaeel NG; Timothy AR; O'Doherty MJ; Hain S; Maisey MN
Leuk Lymphoma; 2000 Nov; 39(5-6):543-53. PubMed ID: 11342337
[TBL] [Abstract][Full Text] [Related]
16. Impact of the 1990 Hong Kong legislation for restriction on sulfur content in fuel.
Wong CM; Rabl A; Thach TQ; Chau YK; Chan KP; Cowling BJ; Lai HK; Lam TH; McGhee SM; Anderson HR; Hedley AJ
Res Rep Health Eff Inst; 2012 Aug; (170):5-91. PubMed ID: 23316618
[TBL] [Abstract][Full Text] [Related]
17. Relapse patterns of localized non-Hodgkin's lymphoma of the head and neck after clinical remission: results of a strict follow-up procedure.
Nakamura K; Sasaki M; Kunitake N; Kimura M; Watanabe T; Sasaki T; Terashima H; Kuwabara Y; Sakai S; Masuda K
Int J Clin Oncol; 2001 Dec; 6(6):302-5. PubMed ID: 11828950
[TBL] [Abstract][Full Text] [Related]
18. General joint frailty model for recurrent event data with a dependent terminal event: Application to follicular lymphoma data.
Mazroui Y; Mathoulin-Pelissier S; Soubeyran P; Rondeau V
Stat Med; 2012 May; 31(11-12):1162-76. PubMed ID: 22307954
[TBL] [Abstract][Full Text] [Related]
19. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
[TBL] [Abstract][Full Text] [Related]
20. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
